Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1705-1712

  Baluna, Roxana ^a   Sausville, Edward A ^b   Stone, Marvin J ^c   Stetler Stevenson, Mary Alice ^b   Uhr, Jonathan W ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; IMMUNOTOXIN; RICIN A; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; BLOOD VESSEL FUNCTION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; CAPILLARY LEAK SYNDROME; FEMALE; FIBRONECTINS; HUMANS; IMMUNOTOXINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RICIN; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029907473     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Frankel, A. E., Tagge, E. P., and Willingham, M. C. Clinical trials of targeted toxins. Semin. Cancer Biol., 6: 307-317, 1995.
2. Sausville, E A., Headlee, D., Stetler-Stevenson, M., Jaffe, E. S., Solomon, D., Figg, W. D., Herdt, J., Kopp, W. C., Rager, H., Steinberg, S. M., Ghetie, V., Uhr, J., Wittes, R. E., and Vitetta, E. S. Continuous infusion of the anti-CD22 immunotoxin. IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a phase I study. Blood, 85: 3457-3465, 1995.
3. Epstein, C., Lynch, T., Shefner, J., Wen, P., Maxted, D., Braman, V., Ariniello, P., Coral, F., and Ritz, J. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int. J. Cancer Suppl., 8: 57-59, 1994.
4. Y damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res., 1: 1589-1594, 1995.
5. Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blattler, W. A., Epstein, C. L., and Nadler, L. M. Anti-B4-blocked ricin - a phase-I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726-737, 1993.
6. Vallera, D. Immunotoxins: will their clinical promise be fulfilled? Blood, 83: 309-317, 1994.
7. Vitetta, E. S., Thorpe, P. E., and Uhr, J. W. Immunotoxins: magic bullets or misguided missiles? Immunol. Today, 14: 252-259, 1993.
8. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T , Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl J. Med., 316: 889-897, 1987.
9. Vial, T., and Descotes, J. Clinical toxicity of IL-2. Drug Safety, 7: 417-433, 1992.
10. Pichert, G., Jost, L. M., Fierz, W., and Stahel, R. A. Clinical and immune modulatory effects of alternative weekly IL-2 and interferon α-2a in patients with advanced renal cell carcinoma and melanoma. Br. J. Cancer, 63: 287-292, 1991.
11. Liberati, A. M., Clinieri, S., Schippa, M., DiClemente, F., Filippo, S., and Grignani, F GM-CSF. clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. Leukemia (Baltimore), 5 (Suppl. 1): 119-122, 1991.
12. Pazdur, R., Ho, D. H., Daugherty, K., Bradner, W. T., Krakoff, I. H., and Raber, M. N. Phase-I trial of FK973-description of a delayed vascular leak syndrome. Invest. New Drugs, 9: 377-382, 1991.
13. Atkins, M. B., Vachino, G., Tilg, H. J., Karp, D. D., Robert, N. J., Kappler, K., and Mier, J. W Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy J Clin. Oncol., 10. 1802-1809, 1992.
14. Bajorin, D. F., Chapman, P. B., Wong, G., Coit, D. G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L., Templeton, M. A., Liu, J., Oettgen, H. F., and Houghton, A. N. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res , 50: 7490-7495, 1990.
15. Woods, W. G., Ramsay, N. K., Weisdorf, D. J., Haake, R., Vallera, D. A., Kim, T. H., Lasky, L., Nesbit, M. E., Bostrom, B., Uckun, F., et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: Lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant., 6: 9-16, 1990.
16. Emminger, W., Emminger-Schmidmeier, W., Peters, C., Susani, M., Hawliczek, R., Hocker, P., and Gadner, H. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut, 61: 219-221, 1990.
17. Zikria, B. A. Mechanisms of multiple system organ failure In: B. A. Zikria, M. O. Oz, and R. W. Carlson (eds.), Reperfusion Injuries and Clinical Capillary Leak Syndrome, pp. 443-489. Armonk, NY. Futura Publishing Co , 1994.
18. Zhang, W., Ewan, P. W., and Lachmann, P. J. The paraproteins in systemic capillary leak syndrome. Clin. Exp. Immunol., 93: 424-429, 1993.
19. McGregor, J. M., Barker, J. N., and MacDonald, D. M. Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. Br. J. Dermatol., 125; 472-474, 1991.
20. Abramov, Y., Galun, E., Granat, M., Barak, V., Abramov, D., Plotkin, V., and Samueloff, A. Postpartum systemic capillary leak syndrome: A possible etiology. Acta Obstet. Gynecol. Scand., 74. 395-398, 1995.
21. Soler-Rodriguez, A. M., Ghetie, M. A., Oppenheimer-Marks, N., Uhr, J. W., and Vitctta, E. S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206: 227-239, 1993.
22. A. Baluna, R., Ghetie, V., Oppenheimer-Marks, N., and Vitetta, E.S. The binding of ricin A-chain to fibronectin; possible implications for vascular leak syndrome in immunotoxin treated patients. Int. J Immunopharmarcol., in press, 1996.
23. Saba, T. M., and Jaffe, E. Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am. J. Med., 68: 577-594, 1980.
24. Saba, T. M. Kinetics of plasma fibronectin: relationship to phagocytic function and lung vascular integrity. In: D. F. Mosher (ed.), Fibronectin, pp. 395-439. San Diego: Academic Press, Inc., 1989.
25. Clark, R. A. F., Dvorak, H. F., and Colvin, R. B. Fibronectin in delayed-typed hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. J. Immunol., 126: 787-793, 1981.
26. Lampugnani, M. G., Resnati, M., Dejana, E., and Marchisio, P. C. The role of integrins in the maintenance of endothelial monolayer integrity. J Cell Biol., 112: 479-490, 1991.
27. Sottile, J., and Wiley, S. Assembly of amino-terminal fibronectin dimers into the extracellular matrix. J. Biol. Chem., 269: 17192-17198, 1994.
28. Luscinskas, F. W., and Lawler, J. Integrins as dynamic regulators of vascular function. FASEB J., 8: 929-938, 1994.
29. Ingber, D. E. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc. Natl. Acad. Sci. USA, 87: 3579-3583, 1990.
30. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thorpe, P. E. A phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res , 51: 4052-4058, 1991.
31. Stone, M., Sausville, E. A., Headlee, D., Lucas, E , Figg, W. D., Stetler-Stevenson, M., Jaffe, E. S , Solomon, D., Lush, R. M., Senderowitz, A., Ghetie, V., Schindler, J., Uhr, J., and Vitetta, E. S. A phase I study of bolus vs. continuous infusion of the anti-CD19immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma. Blood, in press, 1996.
32. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M , Richardson, J., Ghetie, V , Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
33. Dyke, M. P., and Forsyth, K. D. Decreased plasma fibronectin concentrations in preterm infants with septicaemia. Arch. Dis. Child., 68: 557-560, 1993.
34. Annest, C., Scovill, W. A , Blumenstock, F. A., Stratton, H. H., Newell, C., Paloski, W. H., Saba, T. M., and Powers, S. R. Increased creatinine clearance following cryoprecipitate infusion in trauma and surgical patients with decreased renal function. J. Trauma, 20: 726-732, 1980.
35. 2 surface binding glycoprotein therapy during sepsis. Ann. Surg., 188: 521-529, 1978.
36. Saba, T. M., Blumenstock, F. A., Shah, D. M., Landaburu, R. H., Hrinda, M. E., Deno, D. C., Holman, J. J. J., Cho, E., Pherlan, C., and Cardarelli, P. M. Reversal of opsonic deficiency in surgical, trauma and burn patients by infusion of purified human plasma fibronectin. Am. J. Med., 80: 229-240, 1986.
37. Mauviel, A., Daireaux, M., Redini, F , Galera, P., Loyau, G., and Pujol, J. P. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett., 236: 47-52, 1988.
38. Cheng, C. Y., Leggett, C. G., and Reese, A. C. Role of prostaglandins in controlling plasma fibronectin levels. Proc. Soc. Exp. Biol. Med., 188: 444-450, 1988.
39. Ozaki, T., Moriguchi, H., Nakamura, Y., Kamei, T., Yasuoka, S., and Ogura, T. Regulatory effect of prostaglandin E2 on fibronectin release from human alveolar macrophages. Am. Rev. Respir. Dis., 141: 965-969, 1990.
40. Mauviel, A., Kahari, V. M., Heino, J., Daireaux, M., Hartmann, D. J., Loyau, G., and Pujol, J. P. Gene expression of fibroblast matrix proteins is altered by indomethacin. FEBS Lett., 231: 125-129, 1988.
41. Cotran, R. S., Pober, J. S., Gimbrone, M. A., Jr., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., and Lotze, M. T. Endothelial activation during mterleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J. Immunol., 140: 1883-1888, 1988.
42. Pober, J. S., and Cotran, R. S. Cytokines and endothelial cell biology. Physiol. Rev , 70: 427-451, 1990.
43. Mantovani, A., Bussolino, F., and Dejana, E. Cytokine regulation of endothelial cell function. FASEB J., 6: 2591-2599, 1992.
44. Ortiz, A., Alonso, J., Gomez-Chiarri, M., Lerma, L , Seron, D., Condom, E., Gonzalez, E., and Egido, J. Fibronectin (Fn) decreases glomerular lesions and synthesis of tumour necrosis factor-alpha (TNF-α), platelet-activating factor (PF) and FN in proliferative glomerulonephritis. Clin. Exp. Immunol., 101: 334-340, 1995.
45. Wheatley, E. M., Vincent, P. A., McKeown-Longo, P., and Saba, T. M Effect of fibronectin on permeability of normal and TNF-treated lung endothelial cell monolayers. Am. J. Physiol., 204: R90-R96, 1993.
46. Dubinett, S. M., Huang, M., Lichtenstein, A., McBride, W. H., Wang, J., Markovitz, G., Kelley, D., Grody, W. W., Mintz, L. E., and Dhanani, S. Tumor necrosis factor-a plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation. Cell. Immunol., 157: 170-180, 1994.
47. Edwards, M. J., Abney, D. L., Heniford, B T., and Miller, F. N. Passive immunization against tumor necrosis factor inhibits IL-2-induced microvascular alterations and reduces toxicity. Surgery, 112: 480-486, 1992.
48. Grossbard, M., and Nadler, L. M. Immunotoxin therapy of lymphoid neoplasms. Semin. Hematol., 31: 88-97, 1994.